ECSP11011029A - Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional. - Google Patents

Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional.

Info

Publication number
ECSP11011029A
ECSP11011029A EC2011011029A ECSP11011029A ECSP11011029A EC SP11011029 A ECSP11011029 A EC SP11011029A EC 2011011029 A EC2011011029 A EC 2011011029A EC SP11011029 A ECSP11011029 A EC SP11011029A EC SP11011029 A ECSP11011029 A EC SP11011029A
Authority
EC
Ecuador
Prior art keywords
warfarine
therapy
treat
salt
same
Prior art date
Application number
EC2011011029A
Other languages
English (en)
Inventor
Paul A Reilly
Original Assignee
Boehringer Engelheim Internat Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41463075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011029(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Engelheim Internat Gmbh filed Critical Boehringer Engelheim Internat Gmbh
Publication of ECSP11011029A publication Critical patent/ECSP11011029A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un método para prevenir el ictus en un paciente que padece fibrilación auricular, en el que el paciente no tiene factores de riesgo para acontecimientos hemorrágicos mayores, comprendiendo el método administrar al paciente 150 mg b.i.d. de etexilato de dabigatrán, opcionalmente en forma de una sal farmacéuticamente aceptable del mismo.
EC2011011029A 2008-11-11 2011-05-04 Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional. ECSP11011029A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11341308P 2008-11-11 2008-11-11
US23755909P 2009-08-27 2009-08-27

Publications (1)

Publication Number Publication Date
ECSP11011029A true ECSP11011029A (es) 2011-06-30

Family

ID=41463075

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011029A ECSP11011029A (es) 2008-11-11 2011-05-04 Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional.

Country Status (21)

Country Link
US (3) US20110269799A1 (es)
EP (1) EP2355823A1 (es)
JP (1) JP2013510073A (es)
KR (1) KR20110082564A (es)
CN (2) CN103463083A (es)
AR (1) AR074107A1 (es)
AU (1) AU2009315730A1 (es)
BR (1) BRPI0921354A2 (es)
CA (1) CA2738884A1 (es)
CL (1) CL2011000806A1 (es)
CO (1) CO6382133A2 (es)
EA (1) EA201100755A1 (es)
EC (1) ECSP11011029A (es)
IL (1) IL211853A0 (es)
MA (1) MA32785B1 (es)
MX (1) MX2011004796A (es)
NZ (1) NZ592615A (es)
PE (1) PE20110432A1 (es)
TN (1) TN2011000227A1 (es)
TW (1) TW201031651A (es)
WO (1) WO2010055022A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2358368A1 (en) 2008-11-11 2011-08-24 Boehringer Ingelheim International GmbH Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
DK2550966T3 (en) 2011-07-25 2017-02-06 Dritte Patentportfolio Beteili Dabigatran amidoxic acid esters as prodrugs and their use as a drug
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
WO2014001220A1 (en) 2012-06-25 2014-01-03 Boehringer Ingelheim International Gmbh Method for prevention of stroke
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
CN108254216B (zh) * 2018-03-15 2021-04-27 攀钢集团西昌钢钒有限公司 一种高炉槽的矿料取样方法、装置及可读存储介质
WO2020180489A1 (en) * 2019-03-06 2020-09-10 University Of Rochester Anticoagulant compositions and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555581B1 (en) * 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
JP2009543842A (ja) * 2006-07-17 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓血管分野における直接トロンビン阻害薬のための新規適応

Also Published As

Publication number Publication date
AR074107A1 (es) 2010-12-22
US20100322870A1 (en) 2010-12-23
CA2738884A1 (en) 2010-05-20
CN103463083A (zh) 2013-12-25
PE20110432A1 (es) 2011-07-16
MA32785B1 (fr) 2011-11-01
KR20110082564A (ko) 2011-07-19
NZ592615A (en) 2013-06-28
CL2011000806A1 (es) 2011-11-11
US20120277269A1 (en) 2012-11-01
WO2010055022A1 (en) 2010-05-20
CN102209546A (zh) 2011-10-05
TN2011000227A1 (en) 2012-12-17
EP2355823A1 (en) 2011-08-17
MX2011004796A (es) 2011-05-30
BRPI0921354A2 (pt) 2019-09-24
TW201031651A (en) 2010-09-01
IL211853A0 (en) 2011-06-30
US20110269799A1 (en) 2011-11-03
EA201100755A1 (ru) 2011-12-30
AU2009315730A1 (en) 2010-05-20
JP2013510073A (ja) 2013-03-21
CO6382133A2 (es) 2012-02-15

Similar Documents

Publication Publication Date Title
CO6361938A2 (es) Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional
CO6382133A2 (es) Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
MX2022000143A (es) Metodos novedosos.
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
AR119158A1 (es) Tratamientos de angioedema hereditario
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
ECSP13012847A (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación.
AR079552A1 (es) Metodo para el tratamiento de la fibrilacion atrial. formulacion farmaceutica
AR083957A1 (es) Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica
DOP2009000243A (es) Inhibidores de piridopirimidinona de pi3k-alfa en el tratamiento del cancer
AR085173A1 (es) Terapia de combinacion para el tratamiento de enfermedades oncologicas y fibroticas
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
AR082150A1 (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio
AR062658A1 (es) Terapias de combinacion para artritis reumatoide
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
AR088497A1 (es) Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa 4 con atorvastatina
MX2011012310A (es) Tratamiento de insuficiencia cardiaca con fracción de eyeccion normal (icfen).
CL2011000805A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular.
CO6430497A2 (es) Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento
ES2582660T3 (es) Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina
MX2025007253A (es) Metodos para tratar los tumores estromales gastrointestinales con ripretinib
AR099416A1 (es) Terapia combinada para la hipertensión resistente